<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="at: [[inbox]]
Hematology - Hemoglobinopathies - Fast Facts | NEJM Resident 360 Hemoglobinopathies are a group of genetic disorders that affect the structure of hemoglobin within red blood cells, thereby leading to reduced quality or quantity of effective hemoglobin."><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-ph6wrfvo1-htlin222.vercel.app/api/blog?templateTitle=Hematology - Hemoglobinopathies - Fast Facts | NEJM Resident 360"><title>Hematology - Hemoglobinopathies - Fast Facts | NEJM Resident 360</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.720e2c4835986a3891d6eef3a55faa22.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.f7cf62a0b3c093e03ba22dda1b9cfebf.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.89ca39fd23d5ba175ac8cdf8897efccd.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'â€™':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=æœå°‹ placeholder="è«‹è¼¸å…¥åƒæ˜¯ï¼šhypertension ä¹‹é¡çš„ä¾†çœ‹æ²’æœ‰æ²’ä»€éº¼æœ‰è¶£çš„ğŸ³"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>èœ¥èœ´èŠ±åœ’ğŸ¦ğŸŒ±ğŸª´ğŸŒ²</a></h1><div class=spacer></div><div id=search-icon><p>æœå°‹</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">æœå°‹åœ–ç¤º</title><desc id="desc">æ‰“é–‹æœå°‹åœ–æ¨™</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>æ˜äº®æ¨¡å¼</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>é»‘æš—æ¨¡å¼</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>Hematology - Hemoglobinopathies - Fast Facts | NEJM Resident 360</h1><p class=meta>æœ€å¾Œæ›´æ–°æ–¼
Feb 23, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/Hematology%20-%20Hemoglobinopathies%20-%20Fast%20Facts%20%20NEJM%20Resident%20360.md rel=noopener>ğŸªš ç·¨è¼¯åŸå§‹æ–‡ä»¶</a></p><ul class=tags></ul><p>at: <a class="internal-link broken">inbox</a></p><a href=#hematology---hemoglobinopathies---fast-facts--nejm-resident-360><h1 id=hematology---hemoglobinopathies---fast-facts--nejm-resident-360><span class=hanchor arialabel=Anchor># </span>Hematology - Hemoglobinopathies - Fast Facts | NEJM Resident 360</h1></a><p>Hemoglobinopathies are a group of genetic disorders that affect the structure of hemoglobin within red blood cells, thereby leading to reduced quality or quantity of effective hemoglobin. Sickle cell disease is a common and well-studied hemoglobinopathy that causes red blood cells to sickle in low-oxygen tension. In contrast, the thalassemia syndromes, of which alpha- and beta-thalassemia are the most common, result from decreased production of the globin protein.</p><a href=#sickle-cell-disease><h2 id=sickle-cell-disease><span class=hanchor arialabel=Anchor># </span><strong>Sickle Cell Disease</strong></h2></a><p>Sickle cell disease (SCD) is a multisystem condition that can significantly affect a patientâ€™s quality of life. Homozygous hemoglobin S (HbSS), the most common type of sickle cell disease, is caused by a mutation in the beta-globin gene (<em>HBB</em>).Â </p><a href=#signs-and-symptoms><h3 id=signs-and-symptoms><span class=hanchor arialabel=Anchor># </span>Signs and Symptoms</h3></a><p>Clinical manifestations vary significantly and can include:</p><ul><li><p>vaso-occlusive complications</p><ul><li><p>painful episodes</p></li><li><p>stroke</p></li><li><p>acute chest syndrome</p></li><li><p>priapism</p></li><li><p>liver disease</p></li><li><p>splenic sequestration</p></li><li><p>leg ulcers</p></li><li><p>osteonecrosis</p></li></ul></li><li><p>complications of hemolytic anemia (e.g., cholelithiasis and aplastic anemia related to parvovirus B19 infection)</p></li><li><p>infections associated with encapsulated organisms (e.g., <em>Haemophilus influenzae</em> and <em>Streptococcus pneumoniae</em>); osteomyelitis related to organisms such as <em>Staphylococcus aureus</em> or salmonella</p></li></ul><a href=#sickle-cellvaso-occlusive-episodes><h3 id=sickle-cellvaso-occlusive-episodes><span class=hanchor arialabel=Anchor># </span>Sickle CellÂ Vaso-occlusive EpisodesÂ </h3></a><p>Management of sickle cell vaso-occlusive episodes involves pain control and fluid resuscitation to attain euvolemia. Pain control is the priority.</p><ul><li><p><strong>Pain control:</strong> Treatment depends on the patientâ€™s symptoms and should be achieved within 30 minutes.</p><ul><li><p>Avoid cold compress interventions that may precipitate sickling.</p></li><li><p>Treat with acetaminophen.</p></li><li><p>Intravenous opiates may be required in addition to acetaminophen to help with symptoms during a crisis.</p></li><li><p>Provide patient-controlled analgesia.</p></li></ul></li><li><p><strong>Fluid resuscitation:</strong>Â Episodes can be precipitated by a hypovolemic state. Therefore, fluids should be given with the goal of euvolemia. Volume overload can be dangerous in sickle cell patients and should be avoided.</p></li></ul><a href=#clinical-complications-of-scd><h3 id=clinical-complications-of-scd><span class=hanchor arialabel=Anchor># </span>Clinical Complications of SCD</h3></a><p>The following table describes common complications of SCD.</p><a href=#common-clinical-complications-of-sickle-cell-disease><h3 id=common-clinical-complications-of-sickle-cell-disease><span class=hanchor arialabel=Anchor># </span><strong>Common Clinical Complications of Sickle Cell Disease</strong></h3></a><p><strong>(Source: Sickle Cell Disease. N Engl J Med 2017.)</strong></p><p><strong>Acute chest syndrome</strong> is a cause of mortality among patients with SCD and should be considered when patients present with individual or combinations of the following symptoms: fever, chest pain, wheeze, cough, and hypoxemia. Acute chest syndrome can be caused by infections (e.g., community-acquired pneumonia) or thromboembolism. Pulmonary infiltrates involving one or more lobes may be seen on imaging. In one study, the National Acute Chest Syndrome Study Group evaluated 671 episodes and outcomes of acute chest syndrome in 538 adults and children with SCD and found that treatment with transfusions, fluid resuscitation, and antibiotics led to clinical response. Plasma exchange transfusion may be required depending on the severity of acute chest syndrome.</p><a href=#management-of-scd><h3 id=management-of-scd><span class=hanchor arialabel=Anchor># </span>Management of SCD</h3></a><p>Management of SCD should involve:</p><ul><li><p>oxygen</p></li><li><p>pain control</p><ul><li>acetaminophen, ketorolac (monitor creatinine and should be time-limited), opiates, ketamine</li></ul></li><li><p>fluid resuscitation and maintenance to prevent hypovolemia</p></li><li><p>antibiotics</p></li><li><p>blood transfusion</p><ul><li>exchange transfusion required in severe cases</li></ul></li></ul><p><strong>Treatment considerations:</strong></p><ul><li><p>Hydroxyurea has been shown to prolong survival and reduce the incidence of painful crises and rates of hospitalization. In one observational study, hydroxyurea reduced mortality after 9 years of follow-up.</p></li><li><p>Voxelotor is an HbS polymerization inhibitor that binds to hemoglobin and stabilizes the oxygenated state. In a phase 3 study (the HOPE trial), voxelotor increased the hemoglobin level and decreased hemolysis, as compared to placebo.</p></li><li><p>Crizanlizumab, a monoclonal antibody to P-selectin, was associated with a lower rate of sickle cellâ€“related pain crises than placebo in a phase 2 study (the SUSTAIN study).</p></li><li><p>Hematopoietic stem cell transplantation is a potential treatment option, and currently the only curative option.</p></li><li><p>Immunization against encapsulated bacteria should be considered in all patients with SCD.</p></li><li><p>Patients should take supplements including folic acid, vitamin D, multivitamin without iron, if their diet is not deemed adequate.</p></li></ul><a href=#thalassemia><h2 id=thalassemia><span class=hanchor arialabel=Anchor># </span>Thalassemia</h2></a><p>Alpha- and beta-thalassemia are caused by genetic abnormalities related to hemoglobin synthesis. Patients with beta- and alpha-thalassemia minor may have no symptoms or mild anemia. Patients with beta-thalassemia major may require medical support and frequent blood transfusion.</p><p>The following table summarizes the genotypes, phenotypes, and transfusion requirements in patients with Î²-thalassemia:</p><a href=#genotypes-phenotypes-and-transfusion-requirements-in-patients-with-Î²-thalassemia><h3 id=genotypes-phenotypes-and-transfusion-requirements-in-patients-with-Î²-thalassemia><span class=hanchor arialabel=Anchor># </span>Genotypes, Phenotypes, and Transfusion Requirements in Patients with Î²-Thalassemia</h3></a><p><strong>Additional modifiers of phenotype severity may include environmental factors such as coinfection with malaria or polymorphisms that ameliorate the severity of specific complications.16 Î²-Thalassemia intermedia may be associated with deletion forms of Î´Î²-thalassemia and hereditary persistence of fetal hemoglobin (HbF) or dominant (inclusion-body) Î²-thalassemia.16 Clinical manifestations of Î²-thalassemia intermedia and Î²-thalassemia major at presentation, in addition to anemia, may include jaundice, growth retardation, splenomegaly, and facial and bone deformities. HbE denotes hemoglobin E.<br>(Source: Beta-Thalassemia. N Engl J Med 2021.)</strong></p><p>The following figure describes clinical manifestations and treatment-related complications of Î²-thalassemia:</p><a href=#pathophysiology-and-clinical-findings-of-Î²-thalassemia><h3 id=pathophysiology-and-clinical-findings-of-Î²-thalassemia><span class=hanchor arialabel=Anchor># </span>Pathophysiology and Clinical Findings of Î²-Thalassemia</h3></a><p><strong>The circled numbers and letters link complications with causal risk factors.<br>(Source: Beta-Thalassemia. N Engl J Med 2021.)</strong></p><p>Treatment of beta-thalassemia is described in the following diagram:</p><a href=#treatment-options-for-Î²-thalassemia><h3 id=treatment-options-for-Î²-thalassemia><span class=hanchor arialabel=Anchor># </span>Treatment Options for Î²-Thalassemia</h3></a><p><em><em>Panel A shows the treatment options for patients with transfusion-dependent Î²-thalassemia (TDT). T2-weighted (spin-echo) MRI is used to measure liver iron concentration (LIC), whereas T2</em>-weighted (gradient-echo) MRI can be used to measure both LIC and myocardial iron concentration; measurements are reported in milliseconds and can be converted to milligrams of iron per gram of dry weight. Panel B shows the options for patients with nonâ€“transfusion-dependent Î²-thalassemia (NTDT).Â <br>(Source: Beta-Thalassemia. N Engl J Med 2021.)</em>*</p><p><strong>Gene editing:</strong> An emerging therapeutic strategy for both sickle cell disease and beta-thalassemia is disruption ofÂ <em>BCL11a</em>Â transcription by targeted clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 cleavage of an erythroid-specific intronic enhancer. Disrupting the <em>BCL11a</em> locus results in an increase in the production of fetal globin. The need for existing treatment for beta-thalassemia (red cell transfusion and iron chelation) and sickle cell disease (pain management, transfusion, and hydroxyurea) may be negated by the use of gene editing technology.</p><p>See a NEJM Quick Take video describing a recent study of CRISPR-Cas9 gene editing for sickle cell disease and Î²-thalassemia.</p><p><a class="internal-link broken">inbox</a></p></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>â†©ï¸ åå‘é€£çµ</h3><ul class=backlinks><li><a href=/all-list-of-resident360/ data-ctx="Hematology - Hemoglobinopathies - Fast Facts  NEJM Resident 360" data-src=/all-list-of-resident360 class=internal-link>all list of resident360</a></li><li><a href=/hematology/ data-ctx="Hematology - Hemoglobinopathies - Fast Facts  NEJM Resident 360" data-src=/hematology class=internal-link>hematology</a></li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>ğŸ¤¯äº’å‹•åœ–</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>æœ¬ç¶²ç«™æ˜¯ç”± Hsieh-Ting Lin ä»¥â¤ï¸ ç”¨ <a href=https://github.com/jackyzha0/quartz>Quartz</a>é€™å€‹é…·æ±è¥¿ç¨®å‡ºä¾†ğŸª´ , Â© 2023</p><ul><li><a href=https://www.physician.tw/>ğŸ é¦–é </a></li><li><a href=https://www.facebook.com/Tim.H.Lin>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://medium.com/@hsieh-ting-lin>Medium</a></li></ul></footer></div></div></body></html>